Georgia is currently home to 1948 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Autus Valve Pivotal Study
NCT05006404
Recruiting
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-i... Read More
Gender:
ALL
Ages:
Between 18 months and 16 years
Trial Updated:
01/06/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Congenital Heart Disease
Register for Updates
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
NCT05919680
Recruiting
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) t... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/05/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Intestinal Failure Associated Liver Disease
Register for Updates
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning
NCT03311503
Recruiting
This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol. Enrollment of subjects will be agreed upon by representatives of both sites. Data will be... Read More
Gender:
MALE
Ages:
Between 0 years and 5 years
Trial Updated:
01/03/2025
Locations: Emory University/Childrens Healthcare of Atlanta, Atlanta, Georgia
Conditions: Severe Combined Immunodeficiency, X Linked, Gene Therapy
Register for Updates
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: HNSCC
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
NCT06193954
Recruiting
The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Chronic Total Occlusion of Coronary Artery, Chronic Angina
Register for Updates
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
NCT06105918
Recruiting
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 \[177Lu-rhPSMA-10.1\]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided external beam radiotherapy in treating post-prostatectomy patients with prostate cancer that has come back after a period of improvement (recurrent). In this study, radioligand therapy is a radioactive drug called 177Lu-rhPSMA-10.1. It works by binding to PSMA-expressing p... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
NCT05103904
Recruiting
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users
NCT05447325
Recruiting
180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for individual differences in nicotine use prognosis and responsiveness to anti-vaping public service announcements (PSAs). Participants will be assigned randomly to a survey-only control condition, or one... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
12/21/2024
Locations: UGA Bio-imaging Research Center, Athens, Georgia
Conditions: Message Exposure (Sequence: Regular Then Flavor), Message Exposure (Sequence: Flavor Then Regular), No Message Exposure (Control Condition)
Register for Updates
Testing an Integrated Care Model Trial
NCT06448429
Recruiting
This study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (T1D). The duration of the study is 18 months with 4 study survey points. Participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Grady Health System, Atlanta, Georgia
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
NCT05696717
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Theravance Biopharma Investigative Site, Atlanta, Georgia
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Register for Updates
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
NCT04731376
Recruiting
This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testosterone levels. Studies have demonstrated that patients undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass and have improved physical function. Testosterone r... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Register for Updates